- Home
- MVO vs AGEN Comparison
MVO vs AGEN Comparison
Compare MVO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- AGEN
- Stock Information
- Founded
- MVO 2006
- AGEN 1994
- Country
- MVO United States
- AGEN United States
- Employees
- MVO N/A
- AGEN N/A
- Industry
- MVO Oil & Gas Production
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVO Energy
- AGEN Health Care
- Exchange
- MVO Nasdaq
- AGEN Nasdaq
- Market Cap
- MVO 95.7M
- AGEN 96.2M
- IPO Year
- MVO N/A
- AGEN 2000
- Fundamental
- Price
- MVO $5.33
- AGEN $3.32
- Analyst Decision
- MVO
- AGEN Buy
- Analyst Count
- MVO 0
- AGEN 3
- Target Price
- MVO N/A
- AGEN $10.50
- AVG Volume (30 Days)
- MVO 55.1K
- AGEN 357.6K
- Earning Date
- MVO 01-01-0001
- AGEN 03-13-2025
- Dividend Yield
- MVO 17.46%
- AGEN N/A
- EPS Growth
- MVO N/A
- AGEN N/A
- EPS
- MVO 1.46
- AGEN N/A
- Revenue
- MVO N/A
- AGEN $160,427,000.00
- Revenue This Year
- MVO N/A
- AGEN N/A
- Revenue Next Year
- MVO N/A
- AGEN $26.02
- P/E Ratio
- MVO $7.29
- AGEN N/A
- Revenue Growth
- MVO N/A
- AGEN 59.00
- 52 Week Low
- MVO $8.85
- AGEN $2.50
- 52 Week High
- MVO $13.95
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- MVO 30.14
- AGEN 45.96
- Support Level
- MVO $5.36
- AGEN $3.09
- Resistance Level
- MVO $5.62
- AGEN $3.68
- Average True Range (ATR)
- MVO 0.23
- AGEN 0.25
- MACD
- MVO 0.10
- AGEN -0.03
- Stochastic Oscillator
- MVO 59.72
- AGEN 23.00
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These oil and gas properties include producing oil and gas wells.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).